<DOC>
	<DOCNO>NCT02336542</DOCNO>
	<brief_summary>96 TB subject 96 non-TB subject lung disease meet standard divide different group randomize , blind methods.Every subject inject intradermally ESAT6-CFP10 TB-PPD different arm person.Specific γ- IFN ( gamma interferon ) detection need injection.Evaluate sensitivity ( positive coincidence rate ) , specificity ( negative coincidence rate ) coincidence rate ESAT6-CFP10 tuberculosis patient non-tuberculosis patient lung disease , determine optimal dose ESAT6-CFP10 clinical auxiliary diagnosis tuberculosis .</brief_summary>
	<brief_title>Phase IIb Clinical Study Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10</brief_title>
	<detailed_description>Firstly,96 TB ( Tuberculosis ) subject meet standard respectively divide different group randomize , blind method . 1 . ESAT6-CFP10 （5μg/ml）in leave arm； 2 . ESAT6-CFP10 （5μg/ml）in right arm； 3 . ESAT6-CFP10 （10μg/ml）in leave arm； 4 . ESAT6-CFP10 （10μg/ml）in right arm； Inject intradermally ESAT6-CFP10 TB-PPD ( tuberculin purify protein derivative ) different arm subject.For participant clinical research , study uniform leave arm inject drug ( ESAT6-CFP10 TB - PPD ) first , observe 30 min obvious adverse reaction , another drug ( ESAT6-CFP10 TB - PPD ) inject right arm . We need draw blood detect specific γ- IFN injection.Observe record vital sign ( breathe , heart rate , blood pressure temperature ) , skin reaction diameter injection site ( flush induration ) , local reaction ( rash , pain , itch skin mucous membrane ) variety adverse event . Secondly , 96 non-TB subject lung disease divide different group procedure 96 TB subject . Finally , evaluate sensitivity ( positive coincidence rate ) , specificity ( negative coincidence rate ) coincidence rate ESAT6-CFP10 TB patient non-tuberculosis patient lung disease , determine optimal dose ESAT6-CFP10 clinical auxiliary diagnosis tuberculosis , evaluate safety ESAT6-CFP10 clinical auxiliary diagnosis tuberculosis .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<criteria>Inclusion Criteria TB ( tuberculosis ) subject : Diagnosis TB ; 18 65 year ; Consent sign informed consent form ( ICF ) ; Comply followup . Exclusion Criteria TB ( tuberculosis ) subject : advanced cancer , diabetes , copd acute episode , acute/ progressive liver disease kidney disease , congestive heart failure , etc ; Taking part clinical within 3 month involve clinical ; history allergy ; pregnancy lactation ; In mental illness ; Any condition affect trial evaluation . Inclusion Criteria Nontuberculosis subject lung disease : Diagnosis nontuberculosis subject lung disease ; 18 65 year ; Consent sign sign informed consent form ( ICF ) ; Comply followup . Exclusion Criteria Nontuberculosis subject lung disease : advanced cancer , diabetes , copd acute episode , acute/ progressive liver disease kidney disease , congestive heart failure , etc ; Taking part clinical within 3 month involve clinical ; history allergy ; pregnancy lactation ; In mental illness ; Any condition may affect trial evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>diagnosis Tuberculosis</keyword>
	<keyword>ESAT6</keyword>
	<keyword>CFP10</keyword>
	<keyword>skin test</keyword>
	<keyword>diagnostic test</keyword>
</DOC>